Every claim, every source.

This review compares the cardiovascular benefits of eating whole sardines against taking isolated fish-oil supplements. The authors argue that whole sardines provide a "matrix" of nutrients that fish-oil capsules lack: not just EPA and DHA, but calcium, vitamin D, B12, selenium, high-quality protein, and minor compounds (taurine, coenzyme Q10) absent from purified oils. Per 100 grams of cooked sardines, the USDA database reports 24.6 g of protein, 11.5 g of total fat, 473 mg of EPA, 509 mg of DHA, 382 mg of calcium, 4.8 µg of vitamin D, 8.9 µg of B12, and 52.7 µg of selenium. The review surveys randomized trials of sardine consumption versus control diets and concludes that whole-sardine intake produces favourable changes in lipid profile, inflammation markers, and insulin sensitivity, with the additional minerals and protein doing work that omega-3 supplements alone cannot. The framing throughout is that sardines outperform fish-oil supplementation as a delivery vehicle for cardiovascular benefit.

This randomized controlled trial enrolled 71 adults with metabolic syndrome and randomized them to a five-day modified Buchinger-style fast followed by a modified DASH diet versus DASH diet alone. Investigators measured 16S rRNA gut microbiome composition, ambulatory blood pressure, antihypertensive medication requirements, and standard cardiometabolic biomarkers at baseline, immediately post-fast, and at three months follow-up. The fasting plus DASH arm showed greater reductions in systolic blood pressure, in the requirement for antihypertensive medications, and in body-mass index at three months than the DASH-only arm. Gut microbiome analysis identified specific bacterial taxa — including changes in genera linked to short-chain fatty acid production and to microbial pathways relevant to host metabolic regulation — that responded to the fast, with changes that partly persisted into the post-fast period. The paper is one of the few human RCTs to combine a multi-day fasting intervention with comprehensive microbiome characterization and clinically meaningful blood pressure endpoints.

The REDUCE-IT trial randomized 8,179 statin-treated adults with elevated triglycerides and either established cardiovascular disease or diabetes plus risk factors to receive 2 grams of icosapent ethyl twice daily (a purified prescription-grade EPA preparation, total daily dose 4 grams) or matching placebo. After a median follow-up of 4.9 years, the icosapent ethyl arm experienced a 25% relative reduction in the primary composite endpoint of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) compared with placebo. Reductions were observed across multiple individual endpoint components, including cardiovascular death. The trial reignited debate over high-dose omega-3 cardiovascular prevention after several earlier mixed-result trials and stands as the largest, longest, and methodologically strongest RCT supporting a cardiovascular benefit from a specific EPA preparation.

This is the first supervised controlled-feeding trial designed specifically to isolate intermittent fasting's metabolic effects from weight loss. Men with prediabetes were enrolled in a randomized crossover trial: 5 weeks of early time-restricted feeding (eTRF — a 6-hour eating window, with the last meal before 3 p.m.), followed by 5 weeks of a control schedule (12-hour eating window), then crossover. Critically, participants were fed enough food to maintain their weight in both conditions — the eating window changed, but total energy intake did not. Even without weight loss, eTRF improved insulin sensitivity, beta-cell responsiveness, systolic and diastolic blood pressure, oxidative stress (8-isoprostane), and evening appetite. The improvements demonstrate that intermittent fasting's cardiometabolic benefits are not solely mediated by weight loss — circadian alignment of eating and the duration of the daily fasting window have independent effects. The paper has been highly influential because it isolated the eating-window mechanism from the calorie-deficit mechanism.

Open-access narrative review by DiNicolantonio and O'Keefe arguing that the marked increase in dietary linoleic acid (LA, the dominant omega-6 fatty acid in industrial seed oils) is a primary driver of coronary heart disease via the production of oxidized LDL particles enriched in oxidized linoleic acid metabolites (OXLAMs). The paper synthesizes evidence that LA intake has risen from roughly 1–2% of energy in the early 20th century to 8–10% today, that LA accumulates in adipose tissue with a half-life on the order of two years, and that oxidized LA species are inflammatory and atherogenic. The mechanism proposed: industrial vegetable oil consumption raises tissue LA, raises OXLAM production, and contributes to atheroma formation independent of cholesterol per se.

This EFSA Scientific Committee statement weighs the cardiovascular and neurodevelopmental benefits of fish consumption against the risks of methylmercury exposure across the European population. It builds on EFSA's 2012 opinion which set the tolerable weekly intake (TWI) for methylmercury at 1.3 µg/kg body weight — meaning a 70 kg adult can safely consume about 91 µg/week. The 2015 statement identifies the dominant European mercury sources by species: tuna (the largest single contributor in adult diets), swordfish, cod, whiting, and pike. Notably, sardines are not on this high-mercury list. The statement acknowledges new epidemiological data (Seychelles cohort) showing that the long-chain omega-3s from fish may counteract some methylmercury toxicity — a benefit-risk tradeoff that favors lower-mercury species like sardines. EFSA's conclusion is risk-tiered: vulnerable groups (pregnant women, children, high-fish consumers up to 6× TWI) should choose lower-mercury species; the general adult population can consume fish at moderate intake without exceeding the TWI.

The 2012 European Union health-claim regulation that defines the regulatory threshold for what counts as a polyphenol-active olive oil. The claim — "olive oil polyphenols contribute to the protection of blood lipids from oxidative stress" — is authorised only for olive oils that deliver at least 5 milligrams of hydroxytyrosol and its derivatives (oleuropein complex and tyrosol) per 20 grams of olive oil consumed. That works out to a tissue-relevant 250 mg per kilogram of olive oil at the daily-intake reference of 20 g. The claim is supported by a body of EFSA-reviewed mechanistic and intervention evidence on phenolic compounds and oxidative stress markers, and is the most widely cited regulatory basis for the "extra virgin olive oil polyphenols are different from refined olive oil" distinction. The regulation is also the EU's reference point for "extra virgin" olive oil quality grading more broadly (acidity ≤0.8%, panel test, polyphenol content). Refined olive oil typically loses 84–87% of polyphenol content during refining.

This 12-week randomized trial compared a carbohydrate-restricted diet (12 percent carb / 59 percent fat / 28 percent protein) with a low-fat diet (56 percent carb / 24 percent fat / 20 percent protein) in 40 adults with atherogenic dyslipidemia — the metabolic-syndrome phenotype defined by high triglycerides, low HDL, central adiposity, and insulin resistance. Both diets were calorie-restricted to similar levels. Both produced improvements, but the carbohydrate-restricted arm consistently outperformed the low-fat arm across nearly every endpoint that defines metabolic syndrome. Glucose dropped 12 percent in the carb-restricted group; insulin fell 50 percent; insulin sensitivity improved 55 percent; body weight dropped 10 percent; adiposity dropped 14 percent. The lipid panel was the most striking divergence: triglycerides fell 51 percent on carb restriction (versus a smaller drop on low-fat), HDL rose 13 percent (versus no change), and the total-cholesterol-to-HDL ratio improved 14 percent more on carb restriction. The paper's interpretation is that the metabolic syndrome is fundamentally a carbohydrate-intolerance phenotype, and that restricting carbs addresses the upstream driver more directly than restricting fat does.

This is the Cochrane Collaboration's systematic review and meta-analysis of omega-3 PUFA supplementation in adults with type 2 diabetes. Hartweg and colleagues identified 23 randomised controlled trials totalling 1,075 participants, with intervention durations up to 8 months. Omega-3 was compared against vegetable oil or placebo across the included studies. The headline findings: omega-3 supplementation in T2D meaningfully lowered triglycerides and VLDL cholesterol — the primary cardiometabolic risk factors omega-3 was theoretically expected to improve. There was a small possible signal toward higher LDL cholesterol, though the subgroup results did not reach statistical significance. Critically, glycemic control — HbA1c, fasting glucose — was not affected by omega-3 supplementation. No significant adverse effects were reported across the trials. The Cochrane verdict: omega-3 in T2D produces favorable lipid changes but does not lower blood sugar or independently treat diabetes. The intervention is safe; it is not a glycemic therapy.

This JAMA evidence synthesis remains the most-cited single statement on whether fish consumption is, on balance, beneficial or harmful given the dual presence of cardioprotective omega-3 fatty acids and contaminants like methylmercury and PCBs. Mozaffarian and Rimm reviewed the strength of evidence on both sides for adults and for vulnerable groups (children, women of childbearing age) and reached an unambiguous conclusion: the benefits dominate the risks for adult populations. Their pooled estimate found that modest fish consumption — 1–2 servings per week, particularly fatty species rich in EPA and DHA — reduces coronary death risk by 36 percent and total mortality by 17 percent. They identified an EPA+DHA intake of about 250 mg/day as sufficient for primary cardiovascular prevention. For pregnant women and young children, they recommended species selection to minimize methylmercury exposure (avoiding swordfish, king mackerel, tilefish, shark) while still consuming two servings of lower-mercury fish per week. The paper's framing — benefits substantially outweigh risks — has anchored most subsequent dietary fish guidance.

This is the paper that introduced the Omega-3 Index — the proportion of EPA plus DHA in red-blood-cell membranes — as a clinical biomarker for coronary heart disease risk. Harris and von Schacky synthesized epidemiological data from primary and secondary cardiovascular prevention studies to argue that membrane omega-3 status, not just dietary intake, was the relevant risk variable. Their cutoffs have since become the field standard: an Omega-3 Index of 8 percent or higher is associated with substantial cardioprotection, while an index of 4 percent or lower is associated with the highest risk. The paper proposed the Index as a "novel, physiologically relevant, easily modified, independent, and graded" risk factor, comparable in clinical utility to LDL cholesterol or blood pressure. The biomarker has since become commercially available (OmegaQuant being the dominant test provider, founded by Harris) and has been adopted as a tracking metric in many clinical and research contexts. The original paper has been cited several thousand times and seeded a substantial follow-on literature.

GISSI-Prevenzione enrolled 11,324 Italian adults who had survived a recent myocardial infarction, randomizing them to one of four arms: n-3 polyunsaturated fatty acid supplementation (1 g/day of EPA + DHA ethyl esters), vitamin E supplementation, both, or neither. After 3.5 years of follow-up, the n-3 PUFA arm showed a statistically significant reduction in the combined primary endpoint of death, nonfatal myocardial infarction, and stroke compared with control. The benefit appeared early — within the first months — and was driven primarily by reductions in cardiovascular mortality and sudden cardiac death rather than by reductions in nonfatal infarction. Vitamin E supplementation did not significantly affect outcomes. The trial is one of the foundational pieces of evidence supporting omega-3 supplementation in secondary cardiovascular prevention and was influential in shaping European Society of Cardiology and American Heart Association recommendations on fish and omega-3 intake.